

# Lun-Xiu Qin

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9482061/publications.pdf>

Version: 2024-02-01

52  
papers

5,721  
citations

172457

29  
h-index

189892

50  
g-index

53  
all docs

53  
docs citations

53  
times ranked

8290  
citing authors

#	ARTICLE	IF	CITATIONS
1	Emerging Regulatory Mechanisms of N6-Methyladenosine Modification in Cancer Metastasis. <i>Phenomics</i> , 2023, 3, 83-100.	2.9	9
2	Rapamycin enhances the anti-tumor activity of cabozantinib in cMet inhibitor-resistant hepatocellular carcinoma. <i>Frontiers of Medicine</i> , 2022, 16, 467-482.	3.4	4
3	Pan-Cancer Analysis Reveals a Distinct Neutrophil Extracellular Trap-Associated Regulatory Pattern. <i>Frontiers in Immunology</i> , 2022, 13, 798022.	4.8	16
4	Characteristics of pre-metastatic niche: the landscape of molecular and cellular pathways. <i>Molecular Biomedicine</i> , 2021, 2, 3.	4.4	42
5	Development of a predictive nomogram for early recurrence of hepatocellular carcinoma in patients undergoing liver transplantation. <i>Annals of Translational Medicine</i> , 2021, 9, 468-468.	1.7	5
6	Exosomal S100A4 derived from highly metastatic hepatocellular carcinoma cells promotes metastasis by activating STAT3. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 187.	17.1	56
7	<sup>68</sup> Ga-FAPI-04 Versus <sup>18</sup> F-FDG PET/CT in the Detection of Hepatocellular Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 693640.	2.8	55
8	Lenvatinib Targets FGF Receptor 4 to Enhance Antitumor Immune Response of Anti-Programmed Cell Death-1 in HCC. <i>Hepatology</i> , 2021, 74, 2544-2560.	7.3	144
9	Liver X Receptor Agonism Sensitizes a Subset of Hepatocellular Carcinoma to Sorafenib by Dual-Inhibiting MET and EGFR. <i>Neoplasia</i> , 2020, 22, 1-9.	5.3	20
10	LncRNA PVT1 induces aggressive vasculogenic mimicry formation through activating the STAT3/Slug axis and epithelial-to-mesenchymal transition in gastric cancer. <i>Cellular Oncology (Dordrecht)</i> , 2020, 43, 863-876.	4.4	28
11	Insulin-like growth factor 1-induced enolase 2 deacetylation by HDAC3 promotes metastasis of pancreatic cancer. <i>Signal Transduction and Targeted Therapy</i> , 2020, 5, 53.	17.1	70
12	The fuel and engine: The roles of reprogrammed metabolism in metastasis of primary liver cancer. <i>Genes and Diseases</i> , 2020, 7, 299-307.	3.4	12
13	The m6A methylation landscape stratifies hepatocellular carcinoma into 3 subtypes with distinct metabolic characteristics. <i>Cancer Biology and Medicine</i> , 2020, 17, 937-952.	3.0	20
14	A Long Non-coding RNA Signature to Improve Prognostic Prediction of Pancreatic Ductal Adenocarcinoma. <i>Frontiers in Oncology</i> , 2019, 9, 1160.	2.8	29
15	ACOT12-Dependent Alteration of Acetyl-CoA Drives Hepatocellular Carcinoma Metastasis by Epigenetic Induction of Epithelial-Mesenchymal Transition. <i>Cell Metabolism</i> , 2019, 29, 886-900.e5.	16.2	98
16	Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 blockade. <i>Gut</i> , 2019, 68, 1653-1666.	12.1	246
17	Transketolase (TKT) activity and nuclear localization promote hepatocellular carcinoma in a metabolic and a non-metabolic manner. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 154.	8.6	54
18	EGFR and c-MET Cooperate to Enhance Resistance to PARP Inhibitors in Hepatocellular Carcinoma. <i>Cancer Research</i> , 2019, 79, 819-829.	0.9	52

#	ARTICLE	IF	CITATIONS
19	Mutated EPHA2 is a target for combating lymphatic metastasis in intrahepatic cholangiocarcinoma. <i>International Journal of Cancer</i> , 2019, 144, 2440-2452.	5.1	19
20	Genome-Wide Association Study Identifies a Genetic Prediction Model for Postoperative Survival in Patients with Hepatocellular Carcinoma. <i>Medical Science Monitor</i> , 2019, 25, 2452-2478.	1.1	10
21	Elevated G6PD expression contributes to migration and invasion of hepatocellular carcinoma cells by inducing epithelial-mesenchymal transition. <i>Acta Biochimica Et Biophysica Sinica</i> , 2018, 50, 370-380.	2.0	79
22	42,573 cases of hepatectomy in China: a multicenter retrospective investigation. <i>Science China Life Sciences</i> , 2018, 61, 660-670.	4.9	51
23	The dual blockade of MET and VEGFR2 signaling demonstrates pronounced inhibition on tumor growth and metastasis of hepatocellular carcinoma. <i>Journal of Experimental and Clinical Cancer Research</i> , 2018, 37, 93.	8.6	27
24	LncRNA PVT1 promotes angiogenesis via activating the STAT3/VEGFA axis in gastric cancer. <i>Oncogene</i> , 2018, 37, 4094-4109.	5.9	275
25	Osteopontin promotes hepatocellular carcinoma progression via the PI3K/AKT/ Twist signaling pathway. <i>Oncology Letters</i> , 2018, 16, 5299-5308.	1.8	26
26	MicroRNA-219-5p Promotes Tumor Growth and Metastasis of Hepatocellular Carcinoma by Regulating Cadherin 1. <i>BioMed Research International</i> , 2018, 2018, 1-10.	1.9	20
27	The Diverse Mechanisms of miRNAs and lncRNAs in the Maintenance of Liver Cancer Stem Cells. <i>BioMed Research International</i> , 2018, 2018, 1-9.	1.9	20
28	Osteopontin alters DNA methylation through up-regulating DNMT1 and sensitizes CD133+/CD44+ cancer stem cells to 5 azacytidine in hepatocellular carcinoma. <i>Journal of Experimental and Clinical Cancer Research</i> , 2018, 37, 179.	8.6	49
29	Long noncoding RNA miR503HG, a prognostic indicator, inhibits tumor metastasis by regulating the HNRNPA2B1/NF- $\kappa$ B pathway in hepatocellular carcinoma. <i>Theranostics</i> , 2018, 8, 2814-2829.	10.0	151
30	Targeting cancer stem cells and their niche: perspectives for future therapeutic targets and strategies. <i>Seminars in Cancer Biology</i> , 2018, 53, 139-155.	9.6	94
31	GOLM1-regulated EGFR/RTK recycling is a novel target for combating HCC metastasis. <i>Science China Life Sciences</i> , 2017, 60, 98-101.	4.9	11
32	Apatinib is effective for treatment of advanced hepatocellular carcinoma. <i>Oncotarget</i> , 2017, 8, 105596-105605.	1.8	45
33	Better cancer-specific survival in young patients with nonmetastatic intrahepatic cholangiocarcinoma: A retrospective study of SEER database.. <i>Journal of Clinical Oncology</i> , 2017, 35, e15637-e15637.	1.6	0
34	Mapping and analyzing the human liver proteome: progress and potential. <i>Expert Review of Proteomics</i> , 2016, 13, 833-843.	3.0	7
35	Complete regression of xenograft tumors using biodegradable mPEG-PLA-SN38 block copolymer micelles. <i>Colloids and Surfaces B: Biointerfaces</i> , 2016, 142, 417-423.	5.0	18
36	miR-192, a prognostic indicator, targets the SLC39A6/SNAIL pathway to reduce tumor metastasis in human hepatocellular carcinoma. <i>Oncotarget</i> , 2016, 7, 2672-2683.	1.8	68

#	ARTICLE	IF	CITATIONS
37	Osteopontin promotes epithelial-mesenchymal transition of hepatocellular carcinoma through regulating vimentin. <i>Oncotarget</i> , 2016, 7, 12997-13012.	1.8	58
38	Transcriptome and proteome of human hepatocellular carcinoma reveal shared metastatic pathways with significant genes. <i>Proteomics</i> , 2015, 15, 1793-1800.	2.2	10
39	Down-regulation of SDF1- $\alpha$ expression in tumor microenvironment is associated with aspirin-mediated suppression of the pro-metastasis effect of sorafenib in hepatocellular carcinoma. <i>Acta Biochimica Et Biophysica Sinica</i> , 2015, 47, 988-996.	2.0	7
40	CAV1 Promotes HCC Cell Progression and Metastasis through Wnt/ $\beta$ -Catenin Pathway. <i>PLoS ONE</i> , 2014, 9, e106451.	2.5	41
41	Hepatic RIG-I Predicts Survival and Interferon- $\gamma$ Therapeutic Response in Hepatocellular Carcinoma. <i>Cancer Cell</i> , 2014, 25, 49-63.	16.8	182
42	Osteopontin is a promoter for hepatocellular carcinoma metastasis: a summary of 10 years of studies. <i>Frontiers of Medicine</i> , 2014, 8, 24-32.	3.4	36
43	Retrospective study of hepatocellular adenomas based on the phenotypic classification system: A report from China. <i>Histology and Histopathology</i> , 2014, 29, 243-9.	0.7	5
44	Integrated Metabolite and Gene Expression Profiles Identify Lipid Biomarkers Associated With Progression of Hepatocellular Carcinoma and Patient Outcomes. <i>Gastroenterology</i> , 2013, 144, 1066-1075.e1.	1.3	199
45	Inflammatory Immune Responses in Tumor Microenvironment and Metastasis of Hepatocellular Carcinoma. <i>Cancer Microenvironment</i> , 2012, 5, 203-209.	3.1	55
46	Identification of microRNA-181 by genome-wide screening as a critical player in EpCAM-positive hepatic cancer stem cells. <i>Hepatology</i> , 2009, 50, 472-480.	7.3	475
47	MicroRNA Expression, Survival, and Response to Interferon in Liver Cancer. <i>New England Journal of Medicine</i> , 2009, 361, 1437-1447.	27.0	778
48	EpCAM-Positive Hepatocellular Carcinoma Cells Are Tumor-Initiating Cells With Stem/Progenitor Cell Features. <i>Gastroenterology</i> , 2009, 136, 1012-1024.e4.	1.3	1,029
49	The predictive value of chromosome 8p deletion for metastasis of hepatocellular carcinoma: a summary of works in 10 years. <i>Frontiers of Medicine in China</i> , 2008, 2, 211-215.	0.1	0
50	Identification of metastasis-related microRNAs in hepatocellular carcinoma. <i>Hepatology</i> , 2008, 47, 897-907.	7.3	634
51	“Three-Grade Criteria” of radical resection for primary liver cancer. <i>Chinese Journal of Clinical Oncology</i> , 2005, 2, 820-823.	0.0	0
52	The prognostic molecular markers in hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2002, 8, 385.	3.3	279